AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31466703 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced protein content formula
Number of subjects: 0
Study 31466703 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 0
Study 28466679 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/day vitamin D
Number of subjects: 92
Study 28466679 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day vitamin D
Number of subjects: 92
Study 27428671 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 602
Study 24811145 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the computerized Intervention-Management-System (IMS)
Number of subjects: 0
Study 21293163 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fluence verteporfin photodynamic therapy (PDT) with 25 mJ/cm², intravitreal ranibizumab 0.3 mg/0.05 ml, intravitreal dexamethasone 200 μg, and oral minocycline 100 mg daily for 3 months
Number of subjects: 19
Study 19267407 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum triglycerides (highest quartile)
Number of subjects: 31473
Study 19267407 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum triglycerides (after adjustment for BMI)
Number of subjects: 31473
Study 19267407 — intervention group
Group type: COMPARATOR
Intervention: Total serum cholesterol, low-density lipoprotein cholesterol, HDL cholesterol
Number of subjects: 31473
Study 16710715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13
Study 16710715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15523353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 minimal phototoxic dose (MPD) 4 times/wk
Number of subjects: 18
Study 15523353 — intervention group
Group type: COMPARATOR
Intervention: 1 MPD twice/wk
Number of subjects: 18
Study 15523353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MPD twice/wk
Number of subjects: 18
Study 15523353 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 MPD twice/wk
Number of subjects: 18
Study 11397860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11397860 — intervention group
Group type: EXPERIMENTAL
Intervention: KTCZ (400 mg orally 4 times daily)
Number of subjects: 47
Study 11397860 — intervention group
Group type: EXPERIMENTAL
Intervention: KTCZ + transdermal testosterone (7.5 mg daily)
Number of subjects: 47
Study 11397860 — intervention group
Group type: EXPERIMENTAL
Intervention: KTCZ + transdermal estradiol (0.05 mg daily)
Number of subjects: 47
Study 11397860 — intervention group
Group type: EXPERIMENTAL
Intervention: KTCZ + testosterone + anastrazole (5 mg orally twice daily)
Number of subjects: 47
Study 9269788 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ MRL 953
Number of subjects: 20
Study 9269788 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study 8342888 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified expiratory technique
Number of subjects: 48
Study 8342888 — intervention group
Group type: COMPARATOR
Intervention: Standard forced expiratory maneuver
Number of subjects: 48
Study 3329489 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision-graft
Number of subjects: 0
Study 3329489 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 935298 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 880
Study 935298 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 880
Study 935298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 935298 — intervention group
Group type: COMPARATOR
Intervention: Any treatment (including placebo)
Number of subjects: 880
Study 31134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (500 ppm F, n=42)
Number of subjects: 114
Study 31134470 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP crème (10% w/v, n=35)
Number of subjects: 114
Study 31134470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice followed by CPP‐ACP crème (n=37)
Number of subjects: 114
Study 31134470 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 114
Study 31615444 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 33
Study 31615444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33
Study 28151887 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized contrast protocol
Number of subjects: 100
Study 28151887 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast protocol
Number of subjects: 100
Study 25454283 — intervention group
Group type: EXPERIMENTAL
Intervention: WPHF NMES (100Hz, 1ms)
Number of subjects: 42
Study 25454283 — intervention group
Group type: COMPARATOR
Intervention: CONV NMES (25Hz, 0.05ms)
Number of subjects: 42
Study 22806087 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated obstructive hypopnea (inspiration through a threshold load)
Number of subjects: 41
Study 22806087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mueller maneuver
Number of subjects: 41
Study 22806087 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory central apnea
Number of subjects: 41
Study 22806087 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 41
Study 21320256 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for mania and maintenance studies
Number of subjects: 0
Study 21320256 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for depression studies
Number of subjects: 0
Study 21320256 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment in maintenance studies
Number of subjects: 0
Study 19263034 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended drotrecogin alfa (activated) 24 microg/kg/h
Number of subjects: 193
Study 19263034 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride placebo
Number of subjects: 193
Study 19263034 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended drotrecogin alfa (activated)
Number of subjects: 193
Study 17672956 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DMBM)
Number of subjects: 30
Study 17672956 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement (Control)
Number of subjects: 30
Study 15041585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (undiluted)
Number of subjects: 30
Study 15041585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (undiluted)
Number of subjects: 30
Study 15041585 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (1:1000 dilution)
Number of subjects: 30
Study 15041585 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (1:1000 dilution)
Number of subjects: 30
Study 11561075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (600 mg)
Number of subjects: 12
Study 11561075 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (80 mg)
Number of subjects: 12
Study 11561075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9205013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing
Number of subjects: 50
Study 9205013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 50
Study 8435186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 628
Study 8435186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 3315285 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine (2-g oral dose)
Number of subjects: 10
Study 3315285 — intervention group
Group type: COMPARATOR
Intervention: Control (without L-leucine)
Number of subjects: 10
Study 29352828 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn-fortified filtered water (2.8 mg Zn/d)
Number of subjects: 186
Study 29352828 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified filtered water
Number of subjects: 186
Study 26786000 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐hesperidin with 50 mg caffeine
Number of subjects: 75
Study 26786000 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐hesperidin with 75 mg caffeine
Number of subjects: 75
Study 26786000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 26786000 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐hesperidin with/without caffeine
Number of subjects: 75
Study 25695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure to radiofrequency electromagnetic fields (EMFs)
Number of subjects: 26
Study 25695646 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 26
Study 23021496 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid testing with risk reduction counseling
Number of subjects: 1281
Study 23021496 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid testing without risk reduction counseling
Number of subjects: 1281
Study 23021496 — intervention group
Group type: COMPARATOR
Intervention: Off-site referral for HIV risk reduction counseling and testing
Number of subjects: 1281
Study 21042200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus buprenorphine for sciatic block
Number of subjects: 103
Study 21042200 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with epinephrine plus normal saline
Number of subjects: 103
Study 21042200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine sciatic block with intramuscular buprenorphine (0.3 mg)
Number of subjects: 103
Study 21042200 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus normal saline intramuscularly
Number of subjects: 103
Study 18186954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 mL, 20 mg) in 10 mL artificial saliva
Number of subjects: 60
Study 18186954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 mL, 20 mg) + morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Number of subjects: 60
Study 18186954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine (5 mL, 20 mg 4 per thousand) in 5 mL artificial saliva
Number of subjects: 60
Study 18186954 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 mL artificial saliva)
Number of subjects: 60
Study 16444450 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d pravastatin
Number of subjects: 42
Study 16444450 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d pravastatin
Number of subjects: 42
Study 16444450 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 42
Study 15566456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion of 5000 U, starting 3 h before the administration of anti-neoplastic agents and continuing for 12 h
Number of subjects: 20
Study 15566456 — intervention group
Group type: COMPARATOR
Intervention: Anti-neoplastic agents alone (Control)
Number of subjects: 20
Study 11774859 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (once daily, 4 mg/d, in the morning)
Number of subjects: 18
Study 11774859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (twice daily, 20 mg/d)
Number of subjects: 18
Study 9032193 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 8
Study 9032193 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 8
Study 8344693 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb IOT4A (0.6 mg, 1.2 mg, 2.4 mg)
Number of subjects: 10
Study 8344693 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb IOT4A (booster immunization)
Number of subjects: 10
Study 8344693 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb IOT4A
Number of subjects: 10
Study 3096820 — intervention group
Group type: EXPERIMENTAL
Intervention: modified 'CHAP II' regimen
Number of subjects: 19
Study 3096820 — intervention group
Group type: COMPARATOR
Intervention: adriamycin and cis‐diamminedichloroplatinum
Number of subjects: 19
Study 3096820 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen, adriamycin, and cis‐diamminedichloroplatinum
Number of subjects: 19
Study 31701153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction (15.5, 11.7, 5.2, 2.4, and 0.4 mg/g)
Number of subjects: 1250
Study 31701153 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction (0.4 mg/g)
Number of subjects: 1250
Study 31701153 — intervention group
Group type: COMPARATOR
Intervention: Standard nicotine content cigarettes (15.5 mg/g; control)
Number of subjects: 1250
Study 29752304 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen 30 or 50 mg/kg IV once weekly
Number of subjects: 0
Study 27602974 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate foam 1%
Number of subjects: 69
Study 27602974 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 69
Study 25158932 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 82
Study 25158932 — intervention group
Group type: COMPARATOR
Intervention: Drug treatments
Number of subjects: 82
Study 22005962 — intervention group
Group type: EXPERIMENTAL
Intervention: New fixation technique using double anchors (group 1)
Number of subjects: 28
Study 22005962 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group 2)
Number of subjects: 28
Study 20098307 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5%
Number of subjects: 125
Study 20098307 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 0.3%
Number of subjects: 125
Study 18284400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus gel 0.3%
Number of subjects: 0
Study 18284400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus cream 0.5%
Number of subjects: 0
Study 18284400 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment 0.005%
Number of subjects: 0
Study 16368287 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1846
Study 16368287 — intervention group
Group type: COMPARATOR
Intervention: ST deviation 0.05 to 0.09 mV
Number of subjects: 1846
Study 16368287 — intervention group
Group type: COMPARATOR
Intervention: ST deviation > or = 0.10 mV
Number of subjects: 1846
Study 16368287 — intervention group
Group type: COMPARATOR
Intervention: Troponin T 0.01 to 0.10 ng/mL
Number of subjects: 1846
Study 16368287 — intervention group
Group type: COMPARATOR
Intervention: Troponin T > 0.10 ng/mL
Number of subjects: 1846
Study 12502990 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene infusion of 2 mg/ml ropivacaine at 6 or 9 ml/h for 48 hours
Number of subjects: 24
Study 12502990 — intervention group
Group type: COMPARATOR
Intervention: Initial interscalene block with 30 ml ropivacaine, 7.5 mg/ml (225 mg)
Number of subjects: 24
Study 11142423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-vegetable diet (12-week intervention)
Number of subjects: 85
Study 11142423 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (habitual Finnish diet)
Number of subjects: 85
Study 8885726 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient management with bed rest, weekly corticosteroids until 32 weeks, and ultrasonographic examination at 2-week intervals.
Number of subjects: 53
Study 8885726 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management with discharge after >72 hours of hospitalization, weekly corticosteroids until 32 weeks, and ultrasonographic evaluations.
Number of subjects: 53
Study 8885726 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient management
Number of subjects: 53
Study 8885726 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 53
Study 8885726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis based on maternal hospital days
Number of subjects: 53
Study 8885726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 1550636 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous labor
Number of subjects: 112
Study 1550636 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous labor with oxytocin augmentation
Number of subjects: 112
Study 1550636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 112
Study 6094450 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of prophylactic cefotaxime
Number of subjects: 0
Study 6094450 — intervention group
Group type: COMPARATOR
Intervention: Single dose of cefotaxime
Number of subjects: 0
Study 31451065 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME Program
Number of subjects: 302
Study 31451065 — intervention group
Group type: COMPARATOR
Intervention: E‐CARE
Number of subjects: 302
Study 29055489 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE guidance on tumor necrosis factor inhibitor (TNFi) therapies
Number of subjects: 17505
Study 27181456 — intervention group
Group type: EXPERIMENTAL
Intervention: Early strategy of renal-replacement therapy (initiated immediately after randomization)
Number of subjects: 620
Study 27181456 — intervention group
Group type: COMPARATOR
Intervention: Delayed strategy of renal-replacement therapy (initiated based on specific criteria)
Number of subjects: 620
Study 27181456 — intervention group
Group type: EXPERIMENTAL
Intervention: Early strategy of renal-replacement therapy
Number of subjects: 620
Study 27181456 — intervention group
Group type: COMPARATOR
Intervention: Delayed strategy of renal-replacement therapy
Number of subjects: 620
Study 25528663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) dalteparin
Number of subjects: 0
Study 25528663 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 22851600 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 0
Study 22851600 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 0
Study 22851600 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/day
Number of subjects: 0
Study 22851600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Liraglutide 1.2 mg/day
Number of subjects: 0
Study 22851600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Liraglutide 1.8 mg/day
Number of subjects: 0
Study 20172652 — intervention group
Group type: EXPERIMENTAL
Intervention: Authorized deception
Number of subjects: 0
Study 20172652 — intervention group
Group type: COMPARATOR
Intervention: Non-authorized deception
Number of subjects: 0
Study 17575559 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sitagliptin doses (25, 50, 100 mg)
Number of subjects: 22
Study 17575559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sitagliptin 100 mg after high fat meal
Number of subjects: 22
Study 17575559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sitagliptin 100 mg fasted
Number of subjects: 22
Study 16354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine followed by docetaxel (1,000 mg/m2 for gemcitabine and 35 mg/m2 for docetaxel, given on days 1, 8, and 15 every 4 weeks)
Number of subjects: 147
Study 16354317 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by gemcitabine (35 mg/m2 for docetaxel and 1,000 mg/m2 for gemcitabine, given on days 1, 8, and 15 every 4 weeks)
Number of subjects: 147
Study 12095002 — intervention group
Group type: EXPERIMENTAL
Intervention: Male simulated patients (SPs)
Number of subjects: 56
Study 12095002 — intervention group
Group type: COMPARATOR
Intervention: Female simulated patients (SPs)
Number of subjects: 56
Study 12669741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 3021
Study 12669741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 3021
Study 12669741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3021
Study 12669741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 3021
Study 12669741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (general)
Number of subjects: 3021
Study 7852533 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) substitution therapy (0.05 U/kg.day for 1 year; 0.03 U/kg.day during the first month)
Number of subjects: 20
Study 7852533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2182237 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 1258
Study 2182237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study 7191651 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam and 20 to 200 mg of methohexital intravenously
Number of subjects: 124
Study 7191651 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of diazepam, 20 to 200 mg of methohexital, and 0.1 mg of fentanyl intravenously
Number of subjects: 124
Study 7191651 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo intravenously
Number of subjects: 124
Study 31216398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI-based strategy
Number of subjects: 918
Study 31216398 — intervention group
Group type: COMPARATOR
Intervention: FFR-based strategy
Number of subjects: 918
Study 28079501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 180
Study 28079501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 26786087 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing session
Number of subjects: 35
Study 26786087 — intervention group
Group type: COMPARATOR
Intervention: Lecture about BBN
Number of subjects: 35
Study 25459211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight loss (12-week program)
Number of subjects: 204
Study 25459211 — intervention group
Group type: COMPARATOR
Intervention: Gradual weight loss (36-week program)
Number of subjects: 204
Study 25459211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for rapid weight loss
Number of subjects: 204
Study 25459211 — intervention group
Group type: COMPARATOR
Intervention: Intention-to-treat analysis for gradual weight loss
Number of subjects: 204
Study 22989372 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated high‐dose bronchial allergen challenges with household dust mites for four consecutive days
Number of subjects: 27